Loading...
Odonate Therapeutics, Inc.
ODTC•PNK
HealthcareBiotechnology
$22005.00
$5005.00(29.44%)
Odonate Therapeutics, Inc. (ODTC) Stock Overview
Explore Odonate Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ODTCStats details for ODTC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ODTCAnalyst Recommendations details for ODTC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
CEO
Mr. Kevin C. Tang
Employees
137
Headquarters
3 East 28th Street, New York, NY
Founded
2017